Type 1 diabetes is a lifelong autoimmune disease in which the pancreas loses its ability to produce insulin, leading to the accumulation of sugar in the bloodstream. High blood sugar is known as hyperglycemia, and it can even prove fatal if not treated. It is estimated that about 2.1 million Americans have type 1 diabetes.
Insulin therapies marketed by Lilly, Novo Nordisk; and Sanofi, to name a few; Sanofi's immune therapy Tzield; CellTrans' cell therapy Lantidra; and AstraZeneca's adjunctive treatment Symlin are some of the FDA-approved treatments for type 1 diabetes. There is no cure yet for this disease.
The company we are profiling today is Lexicon Pharmaceuticals Inc. (LXRX), which is developing an adjunct therapy to insulin for type 1 diabetes in adults.
For comments and feedback: editorial@rttnews.com